Page last updated: 2024-08-21

fluorobenzenes and Disease Exacerbation

fluorobenzenes has been researched along with Disease Exacerbation in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (33.96)	29.6817
2010's	34 (64.15)	24.3611
2020's	1 (1.89)	2.80

Authors

Authors	Studies
Bots, ML; Chen, Y; Fu, L; Hu, B; Hu, H; Karlson, BW; Li, H; Li, X; Li, Z; Meng, X; Nie, Z; Wang, Y; Wei, D; Zhao, B; Zheng, H	1
Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M	4
Canziani, ME; Carvalho, AB; Christofalo, DM; Draibe, SA; Jancikic, AD; Lemos, MM; Sanches, FM; Watanabe, R	1
Aukrust, P; Fucili, A; Grosu, A; Gullestad, L; Kjekshus, J; Latini, R; Maggioni, AP; Masson, S; McMurray, JJ; Nymo, SH; Ueland, T; Yndestad, A	1
Capoulade, R; Chan, KL; Clavel, MA; Côté, N; Després, JP; Dumesnil, JG; Mathieu, P; Pibarot, P; Tam, JW; Teo, KK	1
Branny, M; Brůhová, H; Hájek, P; Matějovič, M; Studenčan, M; Tesař, D; Tomašov, P; Veselka, J; Zemánek, D	1
Campese, VM	1
Capoulade, R; Chan, KL; Clavel, MA; Côté, N; Després, JP; Dumesnil, JG; Fournier, D; Mathieu, P; Pibarot, P; Tam, JW; Teo, KK	1
Amemiya, K; Ando, K; Domei, T; Goya, M; Iwabuchi, M; Shirai, S; Yokoi, H	1
Biacchi, D; Bononi, M; Borrelli, V; Di Marzo, L; Sapienza, P; Sterpetti, AV; Tartaglia, E; Venturini, L	1
Brener, SJ; Hu, T; Ivanc, TB	1
Nicholls, SJ	1
Bybee, KA; Lavie, CJ; O'Keefe, JH	1
Behrendt, M; Brandt-Eliasson, U; Forsberg, GB; Gan, LM; Grönros, J; Hansson, GI; Wikström, J	1
Pedersen, TR	1
Bots, ML; Crouse, JR; Dogan, S; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Plantinga, Y; Raichlen, JS	2
Boffito, M; Collot-Teixeira, S; De Lorenzo, F; Gazzard, B; McGregor, JL; Shotliff, K; Xiao, H	1
Fabbri, G; Maggioni, AP	1
Chang, HJ; Chang, SA; Kim, DH; Kim, HK; Kim, YJ; Lee, HW; Oh, BH; Park, YB; Sohn, DW	1
Balog, C; Bayturan, O; Crowe, TD; Kapadia, S; Lavoie, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Uno, K; Wolski, K	1
Paraskevas, KI	1
Bots, ML; Crouse, JR; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Raichlen, JS	1
Chan, KL; Dumesnil, JG; Ni, A; Tam, J; Teo, K	2
Abel, T; Fehér, J	1
Aikawa, M; Ganz, P; Josephson, L; Kacher, DF; Libby, P; Morishige, K; Weissleder, R	1
Ahn, Y; Cho, JG; Choi, YH; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Ma, EH; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, NS; Youn, HJ	1
Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS	1
Bhagirath, KM; Chan, KL; Dumesnil, JG; Jassal, DS; Karlstedt, E; Tam, JW; Teo, KK; Zeglinski, M	1
Bunck, M; Gaburro, S; Hauschild, M; Landgraf, R; Sartori, SB; Singewald, N	1
Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS	1
Budts, W; Cuypers, JA; Lindemans, J; Mulder, BJ; Pieper, PG; Roos-Hesselink, JW; Takkenberg, JJ; van der Burgh, PH; van der Linde, D; van Dijk, AP; Witsenburg, M; Yap, SC	1
Bots, ML; Crouse, JR; den Ruijter, HM; Evans, GW; Grobbee, DE; Lind, L; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Freedman, B; Kuan, WP; Lee, KK; Lee, VW; Li, EK; Li, M; Li, TK; Shang, Q; Tam, LS; Tomlinson, B; Tseung, L; Yip, GW; Yu, CM	1
Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K	1
Ishihara, M	1
Garcia-Garcia, HM; Okamura, T; Serruys, PW; Shin, ES	1
Einecke, D	1
Bots, ML; Crouse, JR; den Ruijter, HM; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Peters, SA; Raichlen, JS	1
Belch, JJ; Kennedy, G; Khan, F; Kumar, P; Pullar, T	1
Barros, IM; Kristensen, SD; Moura, LM; Pinto, FJ; Ramos, SF; Rocha-Gonçalves, F	1
Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG	1
Daida, H; Hiro, T; Matsuzaki, M; Saito, S; Takayama, T; Yamagishi, M; Yamaguchi, T	1
Abbate, M; Banfi, C; Bellosta, S; Brioschi, M; Canavesi, M; Gelosa, P; Gianella, A; Guerrini, U; Mussoni, L; Nobili, E; Remuzzi, G; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C	1
Chan, KL; Dumesnil, JG; Tam, J; Teo, K	1
Kawachi, H; Khadzhynov, D; Krämer, S; Kron, S; Loof, T; Martini, S; Morgera, S; Neumayer, HH; Peters, H; Shimizu, F; Wang-Rosenke, Y	1
Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E	1
Rahimtoola, SH	1
Cain, VA; Chu, B; Hamar, W; Hatsukami, TS; Kraiss, LW; Liu, F; Neradilek, B; Parker, DL; Polissar, NL; Raichlen, JS; Saam, T; Takaya, N; Underhill, HR; Waterton, JC; Yuan, C; Zhao, XQ	1

Reviews

6 review(s) available for fluorobenzenes and Disease Exacerbation

Article	Year
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides	2014
Rosuvastatin and progression of atherosclerosis. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:7 Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Coronary Vessels; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2008
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Advances in therapy, 2009, Volume: 26, Issue:5 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Kidney Failure, Chronic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2009
[Role of rosuvastatin in current lipid-lowering therapy]. Orvosi hetilap, 2010, Aug-29, Volume: 151, Issue:35 Topics: Acute Coronary Syndrome; Atherosclerosis; C-Reactive Protein; Cholesterol; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Rosuvastatin-induced arrest in progression of renal disease. Cardiology, 2004, Volume: 102, Issue:1 Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
The year in valvular heart disease. Journal of the American College of Cardiology, 2008, Feb-19, Volume: 51, Issue:7 Topics: Animals; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Arabidopsis Proteins; Bioprosthesis; Body Surface Area; Catheterization; Cholesterol, LDL; Coronary Disease; Disease Progression; Echocardiography, Three-Dimensional; Endocarditis, Bacterial; Fluorobenzenes; Heart Valve Diseases; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitral Valve Insufficiency; Mitral Valve Stenosis; Odds Ratio; Practice Guidelines as Topic; Prosthesis Design; Prosthesis Fitting; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Left	2008

Trials

31 trial(s) available for fluorobenzenes and Disease Exacerbation

Article	Year
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study. Stroke, 2022, Volume: 53, Issue:10 Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Fluorobenzenes; Humans; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2022
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International heart journal, 2013, Volume: 54, Issue:1 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Japan; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Pharmacovigilance; Pravastatin; Preventive Health Services; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2013
Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical nephrology, 2013, Volume: 80, Issue:1 Topics: Adult; Aged; Analysis of Variance; Calcinosis; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Polyamines; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sevelamer; Sulfonamides; Tomography, X-Ray Computed	2013
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. European journal of heart failure, 2013, Volume: 15, Issue:7 Topics: Aged; Chemokine CCL21; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Norway; Prognosis; Proportional Hazards Models; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome	2013
Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial. JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:2 Topics: Adult; Aged; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Canada; Chi-Square Distribution; Disease Progression; Female; Fluorobenzenes; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Insulin Resistance; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Time Factors; Ultrasonography; Ventricular Function, Left; Ventricular Remodeling	2013
Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study). The American journal of cardiology, 2014, Feb-01, Volume: 113, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Period; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Troponin I	2014
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study. International heart journal, 2014, Volume: 55, Issue:2 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis. Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:7 Topics: Aged; Cardiovascular Diseases; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial. The Canadian journal of cardiology, 2014, Volume: 30, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Calcium-Binding Proteins; Disease Progression; Echocardiography, Doppler; Extracellular Matrix Proteins; Female; Fluorobenzenes; Humans; Male; Matrix Gla Protein; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2014
Suppressive effects of standard-dose rosuvastatin therapy on the progression of coronary atherosclerosis in Japanese patients: the APOLLO study. Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Artery Disease; Disease Progression; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Stents; Sulfonamides	2014
Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of internal medicine, 2009, Volume: 265, Issue:6 Topics: Aged; Anticholesteremic Agents; Carotid Artery Diseases; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography	2009
Prevention of atherosclerosis in patients living with HIV. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Disease Progression; Double-Blind Method; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2009
Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials. JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:7 Topics: Aged; Atherosclerosis; Calcinosis; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2009
Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2010, Volume: 17, Issue:2 Topics: Aged; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2010
Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation, 2010, Jan-19, Volume: 121, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Cholesterol; Disease Progression; Double-Blind Method; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Failure; Young Adult	2010
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2 Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional	2011
Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Cardiovascular ultrasound, 2011, Feb-07, Volume: 9, Issue:1 Topics: Adult; Aged; Aortic Valve Stenosis; Disease Progression; Echocardiography, Doppler; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure, Diastolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides	2011
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Current medical research and opinion, 2011, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography	2011
Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). The American journal of cardiology, 2011, Jul-15, Volume: 108, Issue:2 Topics: Adolescent; Adult; Aortic Valve; Aortic Valve Stenosis; Belgium; Blood Flow Velocity; Calcinosis; Disease Progression; Double-Blind Method; Echocardiography, Doppler; Female; Fluorobenzenes; Follow-Up Studies; Heart Valve Prosthesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Netherlands; Peptide Fragments; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult	2011
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. American heart journal, 2011, Volume: 161, Issue:6 Topics: Adult; Aged; Aortic Valve Stenosis; Body Mass Index; C-Reactive Protein; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. Journal of internal medicine, 2012, Volume: 271, Issue:3 Topics: Adult; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Reproducibility of Results; Risk; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima; Tunica Media	2012
Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scandinavian journal of rheumatology, 2011, Volume: 40, Issue:6 Topics: Apolipoproteins B; Arthritis, Rheumatoid; Atherosclerosis; Carotid Intima-Media Thickness; Carotid Stenosis; Cholesterol; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Vascular Stiffness	2011
Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect. Journal of hypertension, 2011, Volume: 29, Issue:11 Topics: Aged; Algorithms; Atherosclerosis; Cardiology; Carotid Arteries; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrimidines; Reproducibility of Results; Risk; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media	2011
Effect of two intensive statin regimens on progression of coronary disease. The New England journal of medicine, 2011, Dec-01, Volume: 365, Issue:22 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional	2011
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:1 Topics: Aged; Asian People; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Hypolipidemic Agents; Japan; Longitudinal Studies; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome	2012
Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scottish medical journal, 2012, Volume: 57, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Scotland; Sulfonamides; Treatment Outcome	2012
Rosuvastatin slows the development of diastolic dysfunction in calcific aortic stenosis. The Journal of heart valve disease, 2012, Volume: 21, Issue:4 Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Calcinosis; Diastole; Disease Progression; Echocardiography; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure, Diastolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Left	2012
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultras Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:2 Topics: Adult; Aged; Atherosclerosis; Coronary Artery Disease; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional	2007
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. American heart journal, 2007, Volume: 153, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Echocardiography; Female; Fluorobenzenes; Follow-Up Studies; Heart Valve Prosthesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome	2007
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American heart journal, 2008, Volume: 155, Issue:3 Topics: Aged; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Reproducibility of Results; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2008

Other Studies

16 other study(ies) available for fluorobenzenes and Disease Exacerbation

Article	Year
Statins reduce levels of metalloproteinases in patients with carotid occlusive disease. International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:6 Topics: Aged; Angiography; Asymptomatic Diseases; Carotid Stenosis; Disease Progression; Drug Monitoring; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metalloproteases; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tissue Inhibitor of Metalloproteinases; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler, Color	2014
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression. The Journal of invasive cardiology, 2008, Volume: 20, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional	2008
Intensive lipid intervention in the post-ENHANCE era. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 295, Issue:5 Topics: Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Flow Velocity; Brachiocephalic Trunk; Coronary Circulation; Coronary Vessels; Disease Models, Animal; Disease Progression; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Time Factors; Ultrasonography	2008
Intensive lipid-lowering therapy for patients with aortic stenosis. The American journal of cardiology, 2008, Dec-01, Volume: 102, Issue:11 Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:3 Topics: Animals; Blood Pressure; Collagen; Disease Progression; Fibrosis; Fluorobenzenes; Heart; Heart Failure; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Myocardium; Organ Size; Pyrimidines; Random Allocation; Rats; Rats, Inbred Dahl; Rosuvastatin Calcium; Sulfonamides	2009
Prescribing statins in aortic stenosis: little to lose, much to gain. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2010, Volume: 37, Issue:2 Topics: Aortic Valve Stenosis; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation, 2010, Oct-26, Volume: 122, Issue:17 Topics: Animals; Aorta, Abdominal; Atherosclerosis; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Ferrosoferric Oxide; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Magnetic Resonance Imaging; Male; Metal Nanoparticles; Nanoparticles; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day. The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9 Topics: Angina Pectoris; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Ultrasonography, Interventional	2010
Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions. PloS one, 2011, Feb-28, Volume: 6, Issue:2 Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Animal; Corticosterone; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Expressed Emotion; Fear; Fluorobenzenes; Male; Mice; Neurokinin-1 Receptor Antagonists; Phobic Disorders; Physical Conditioning, Animal; Piperidines; Psychopathology; Triazoles; Up-Regulation	2011
Intensive lipid-lowering therapy with statins for primary prevention. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:1 Topics: Asian People; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2012
Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study. The international journal of cardiovascular imaging, 2012, Volume: 28, Issue:7 Topics: Aged; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Necrosis; Odds Ratio; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Calcification	2012
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins]. MMW Fortschritte der Medizin, 2011, Dec-08, Volume: 153, Issue:49-50 Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate	2011
Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time. Current medical research and opinion, 2012, Volume: 28, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Humans; Male; Middle Aged; Placebos; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tunica Intima	2012
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. The American journal of pathology, 2007, Volume: 170, Issue:4 Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen; Disease Progression; Fibrinogen; Fibrinolysin; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Electron; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Podocytes; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides	2007
Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. American journal of physiology. Renal physiology, 2008, Volume: 294, Issue:4 Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fluorobenzenes; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Male; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tetrazoles	2008